Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Apr;50(4):476-82.
doi: 10.1038/bmt.2014.312. Epub 2015 Feb 2.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

J R Passweg  1 , H Baldomero  1 , P Bader  2 , C Bonini  3 , S Cesaro  4 , P Dreger  5 , R F Duarte  6 , C Dufour  7 , J H F Falkenburg  8 , D Farge-Bancel  9 , A Gennery  10 , N Kröger  11 , F Lanza  12 , A Nagler  13 , A Sureda  6 , M Mohty  14 ; European Society for Blood and Marrow Transplantation (EBMT)
Affiliations
Multicenter Study

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

J R Passweg et al. Bone Marrow Transplant. 2015 Apr.

Abstract

A record number of 39,209 HSCT in 34,809 patients (14,950 allogeneic (43%) and 19,859 autologous (57%)) were reported by 658 centers in 48 countries to the 2013 survey. Trends include: more growth in allogeneic than in autologous HSCT, increasing use of sibling and unrelated donors and a pronounced increase in haploidentical family donors when compared with cord blood donors for those patients without a matched related or unrelated donor. Main indications were leukemias, 11,190 (32%; 96% allogeneic); lymphoid neoplasias, 19,958 (57%; 11% allogeneic); solid tumors, 1543 (4%; 4% allogeneic); and nonmalignant disorders, 1975 (6%; 91% allogeneic). In patients without a matched sibling or unrelated donor, alternative donors are used. Since 2010 there has been a marked increase of 96% in the number of transplants performed from haploidentical relatives (802 in 2010 to 1571 in 2013), whereas the number of unrelated cord blood transplants has slightly decreased (789 in 2010 to 666 in 2013). The use of donor type varies greatly throughout Europe.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative proportions of indications for an HSCT in Europe in 2013. (a) Proportions of disease indications for an allogeneic HSCT in Europe in 2013. (b) Proportions of disease indications for an autologous HSCT in Europe in 2013.
Figure 2
Figure 2
Transplant rates in Europe (= total number of HSCT per 10 million inhabitants) by participating country, showing 15-year trends 1998–2013. (a) Allogeneic transplant rates per 10 million population in 1998–2013 (b) Autologous transplant rates per 10 million population in 1998–2013.
Figure 3
Figure 3
Absolute numbers by transplant and donor type 1998–2013. (a) Absolute numbers of allogeneic and autologous HSCT in Europe in 1998–2013. (b) Absolute numbers of sibling donor and unrelated donor HSCT in Europe 1998–2013. (c) Absolute numbers of haploidentical and cord blood HSCT in Europe 1998–2013.
Figure 4
Figure 4
Disease indications by donor type in 2013. (a) Proportions of disease indications in 2013 for sibling donor HSCT. (b) Proportions of disease indications in 2013 for haplo-identical donor HSCT. (c) Proportions of disease indications in 2013 for unrelated donor HSCT. (d) Proportions of disease indications in 2013 for cord blood HSCT.
Figure 5
Figure 5
Transplant rates for sibling donor, unrelated donor, haploidentical donor and cord blood HSCT in Europe in 2013 for the 15 countries with the highest transplant rates.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–1826. - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–1475. - PubMed
    1. Ljungman P, Bregni M, Brune M, Cornelissen J, deWitte T, Dini G, et al. European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219–234. - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–1624. - PMC - PubMed
    1. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant. 2011;46:174–191. - PubMed

Publication types